Mindwalk Holdings Corp. · NASDAQ:HYFT
Mindwalk — ImmunoPrecise Antibodies — Q2 2025 Earnings Presentation
17 slides from Mindwalk's earnings presentation, Dec 10, 2024
Slide 1: FY 2025 Q2 Earnings Presentation
FY 2025 Q2 Earnings Presentation December 10, 2024 | ir.ipatherapeutics.com | NASDAQ: IPA Presented by Dr. Jennifer Bath, IPA CEO
Slide 2: Disclosures
Disclosures Disclaimer This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilitie
Slide 3: Fiscal Year 2025 Q2 Business Update
Fiscal Year 2025 Q2 Earnings Call Fiscal Year 2025 Q2 Business Update ir.ipatherapeutics.com | NASDAQ:IPA ©2024 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiary of IPA. BioStrand and LENSai ar
Slide 4: Headquarters will be relocating to Austin, Texas
Fiscal Year 2025 Q2 Earnings Call Corporate Update Strategic Development & Leadership Headquarters will be relocating to Austin, Texas Austin has rapidly emerged as a global hub for artificial intelligence and biotechnology + ir.ipatherapeutics.com | NASDAQ:IPA ©2024 ImmunoPrecise Antibodies LTD. Al
Slide 5: Leadership update and strategic divestitures
Fiscal Year 2025 Q2 Earnings Call Corporate Update Strategic Development & Leadership Leadership update Strategic divestitures: Dr. Barry A. Springer, Retiring from streamlining for growth IPA Board of Directors Two European wet labs • Utrecht • Oss, the Netherlands ir.ipatherapeutics.com | NASDAQ:I
Slide 6: Commitment to financial discipline
Fiscal Year 2025 Q2 Earnings Call Corporate Update Cost Cutting Measures Commitment to Concluding financial discipline relationship with Executive compensation updates Quantum IR Focused on a responsive investor relations strategy ir.ipatherapeutics.com | NASDAQ:IPA ©2024 ImmunoPrecise Antibodies LT
Slide 7: Strategic Partnerships and Industry Engagement
Fiscal Year 2025 Q2 Earnings Call Corporate Update Strategic Partnerships and Industry Engagement AI-Driven Drug Discovery Summit TECHday Highlights Fireside Chat “The speed of the best Google algorithms and Titled: “Beyond Conventional Biologics: The machine learning is nothing compared to what Int
Slide 8: Strategic Development: rebranding initiative
Fiscal Year 2025 Q2 Earnings Call Corporate Update Strategic Development We’re excited to announce our rebranding initiative Science-powered, technology-driven, unified and amplified. Our transformation reflects a future of limitless potential ir.ipatherapeutics.com | NASDAQ:IPA ©2024 ImmunoPrecise
Slide 9: Collaboration and clinical success highlights
Fiscal Year 2025 Q2 Earnings Call Business update Collaboration and clinical success highlights TATX-112 breakthrough in Material transfer agreement OncoResponse clinical ADC development with Biotheus success update Significant milestone update: Significant development: IPA Rabbit B cell Select® dis
Slide 10: Partnership and clinical success highlights
Fiscal Year 2025 Q2 Earnings Call Business update Partnership and clinical success highlights Mayo Clinic collaboration: Collaboration with leading Additional collaborative talks with advancing anti-aging research semiconductor company semiconductor innovators underway Rabbit B cell Select® platform
Slide 11: BioStrand commercialization highlights
Fiscal Year 2025 Q2 Earnings Call Business update BioStrand commercialization highlights Dual revenue model combines application- AWS partnership and based pricing through portal and API access deployment progress Application based services deployed Data management subscriptions Currently in the Fou
Slide 12: Fiscal Year 2025 Q2 Financial Update
Fiscal Year 2025 Q2 Earnings Call Fiscal Year 2025 Q2 Financial Update ir.ipatherapeutics.com | NASDAQ:IPA ©2024 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiary of IPA. BioStrand and LENSai a
Slide 13: Quarterly Revenue
Fiscal Year 2025 Q2 Earnings Call Quarterly Revenue $7,0 M $6,5 M $6,1 M $6,1 M $6,2 M $6,0 M $5,7 M $5,6 M $5,3 M $5,2 M $5,2 M $5,2 M $4,7 M $4,8 M $5,0 M $4,7 M $4,6 M $4,0 M $3,0 M $2,0 M $1,0 M $0,0 M Q1 Q2 Q3 Q4 FY25 FY24 FY23 FY22 Al l values listed i n CAD. ir.ipatherapeutics.com | NASDAQ:IP
Slide 14: Focus on growth through R&D and Sales & Marketing
Fiscal Year 2025 Q2 Earnings Call Focus on growth through R&D and Sales & Marketing Research & Development Sales & Marketing General & Administrative $1,5 M $5,0 M $1,2 M $1,5 M $1,2 M $4,0 M $3,3 M $3,3 M $1,0 M $0,9 M $1,0 M $0,8 M $3,0 M $2,0 M $0,5 M $0,5 M $1,0 M $0,0 M $0,0 M $0,0 M Q2'25 Q2'2
Slide 15: Net Loss of $2.6M, ($0.09) per share
Fiscal Year 2025 Q2 Earnings Call Net Loss of $2.6M, equivalent to ($0.09) per share (basic & diluted) Net Loss Earnings Per Share $0,0 M 0,00 -$1,0 M -$2,6 M -$2,4 M -0,05 -0,09 -0,10 -$2,0 M -0,10 -$3,0 M -$4,0 M -0,15 Q2 '25 Q2 '24 Q2 '25 Q2 '24 Al l values listed i n CAD. ir.ipatherapeutics.com
Slide 16: Ending Q2 Cash Balance of $3.6M
Fiscal Year 2025 Q2 Earnings Call Ending Q2 Cash Balance of $3.6M Oct 31, 2024 $3,6 M April 30, 2024 $3,5 M $2,0 M $2,2 M $2,4 M $2,6 M $2,8 M $3,0 M $3,2 M $3,4 M $3,6 M $3,8 M Six Months Ended Oct 31, 24 $4,8 M $0,3 M -$0,3 M -$4,1 M Ops Burn Capex & LHI Financing Total Cash Provided Al l values l
Slide 17: Q&A FY 2025 Q2 Earnings Call
Q&A FY 2025 Q2 Earnings Call The HUB of December 10, 2024| ir.ipatherapeutics.com | NASDAQ: IPA TSXV: IPA Biotherapeutic ©2024 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiary of ImmunoPrecise
ImmunoPrecise Antibodies — Q2 2025 Earnings Presentation on 6ix